These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12040335)

  • 21. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.
    Lindahl B; Venge P; Wallentin L
    J Am Coll Cardiol; 1997 Jan; 29(1):43-8. PubMed ID: 8996293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
    Mälarstig A; Lindahl B; Wallentin L; Siegbahn A
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1667-73. PubMed ID: 16627810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia.
    Nørgaard BL; Andersen K; Dellborg M; Abrahamsson P; Ravkilde J; Thygesen K
    J Am Coll Cardiol; 1999 May; 33(6):1519-27. PubMed ID: 10334417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials.
    Damman P; van Geloven N; Wallentin L; Lagerqvist B; Fox KA; Clayton T; Pocock SJ; Hirsch A; Windhausen F; Tijssen JG; de Winter RJ
    JACC Cardiovasc Interv; 2012 Feb; 5(2):191-9. PubMed ID: 22361604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction.
    Wong GC; Morrow DA; Murphy S; Kraimer N; Pai R; James D; Robertson DH; Demopoulos LA; DiBattiste P; Cannon CP; Gibson CM
    Circulation; 2002 Jul; 106(2):202-7. PubMed ID: 12105159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
    Norhammar A; Malmberg K; Diderholm E; Lagerqvist B; Lindahl B; Rydén L; Wallentin L
    J Am Coll Cardiol; 2004 Feb; 43(4):585-91. PubMed ID: 14975468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
    Lagerqvist B; Husted S; Kontny F; Ståhle E; Swahn E; Wallentin L;
    Lancet; 2006 Sep; 368(9540):998-1004. PubMed ID: 16980115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia.
    Lüscher MS; Thygesen K; Ravkilde J; Heickendorff L
    Circulation; 1997 Oct; 96(8):2578-85. PubMed ID: 9355897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective R.OS.A.I.-2 registry.
    Registro Osservazionale Angina Instabile Investigators
    Ital Heart J; 2003 Nov; 4(11):782-90. PubMed ID: 14699708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study.
    Hirsch A; Windhausen F; Tijssen JG; Verheugt FW; Cornel JH; de Winter RJ;
    Lancet; 2007 Mar; 369(9564):827-835. PubMed ID: 17350451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.
    Lindahl B; Lindbäck J; Jernberg T; Johnston N; Stridsberg M; Venge P; Wallentin L
    J Am Coll Cardiol; 2005 Feb; 45(4):533-41. PubMed ID: 15708700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early invasive versus selectively invasive management for acute coronary syndromes.
    de Winter RJ; Windhausen F; Cornel JH; Dunselman PH; Janus CL; Bendermacher PE; Michels HR; Sanders GT; Tijssen JG; Verheugt FW;
    N Engl J Med; 2005 Sep; 353(11):1095-104. PubMed ID: 16162880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving outcomes in acute coronary syndromes--the FRISC II trial.
    Kontny F
    Clin Cardiol; 2001 Mar; 24(3 Suppl):I3-7. PubMed ID: 11286312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The FRISC experience with troponin T. Use as decision tool and comparison with other prognostic markers.
    Lindahl B; Venge P; Wallentin L
    Eur Heart J; 1998 Nov; 19 Suppl N():N51-8. PubMed ID: 9857941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognosis in unstable coronary artery disease. Multimarker strategy is the best basis for the therapeutic choice].
    James S; Lindahl B; Siegbahn A; Stridsberg M; Venge P; Wallentin L
    Lakartidningen; 2004 Apr; 101(17):1514-9, 1521-2. PubMed ID: 15150954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy.
    Giannitsis E; Wallentin L; James SK; Bertilsson M; Siegbahn A; Storey RF; Husted S; Cannon CP; Armstrong PW; Steg PG; Katus HA;
    Eur Heart J Acute Cardiovasc Care; 2017 Sep; 6(6):500-510. PubMed ID: 27044282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
    Planer D; Mehran R; Ohman EM; White HD; Newman JD; Xu K; Stone GW
    Circ Cardiovasc Interv; 2014 Jun; 7(3):285-93. PubMed ID: 24847016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
    Toss H; Lindahl B; Siegbahn A; Wallentin L
    Circulation; 1997 Dec; 96(12):4204-10. PubMed ID: 9416883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of biochemical markers of infarction for diagnosing perioperative myocardial infarction and early graft occlusion after coronary artery bypass surgery.
    Holmvang L; Jurlander B; Rasmussen C; Thiis JJ; Grande P; Clemmensen P
    Chest; 2002 Jan; 121(1):103-11. PubMed ID: 11796438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.